Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study to Evaluate TZLS-501 for the Treatment of COVID-19 Patients

Next Previous
Trial Profile

A Clinical Study to Evaluate TZLS-501 for the Treatment of COVID-19 Patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TZLS 501 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Tiziana Life Sciences

Most Recent Events

  • 04 Aug 2020 According to a Tiziana Life Sciences media release, the Company intends to initiate the clinical study in Q1 2021 and will work with the following CROs FHI Clinical, STC Biologics, Sciarra Labs, ITR Laboratories Canada.
  • 03 Jul 2020 New trial record
  • 29 Jun 2020 According to a Tiziana Life Sciences media release, the initiation of GMP manufacturing of TZLS-501 with STC is a timely step forward toward expediting development of a potentially innovative treatment for COVID-19 patients.Together with a strong track record of pharmaceutical, regulatory and process development know-how, the company is uniquely positioned to advance TZLS-501 to the clinic.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top